GlassScriptPhysician profile
Ronald A Nelson
NPI 1760407944
$100,849.66
in general payments reported to CMS, 2019-2025
48 companies · $19K in 2025
The $19K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $3,190 · 2021: $3,893 · 2022: $23K · 2023: $19K · 2024: $14K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $13K · Travel and Lodging: $776 · Education: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,001.50 |
| Food and Beverage | $12,613.83 |
| Travel and Lodging | $775.88 |
| Education | $409.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $49,404.88 | 2019-2025 | |
| Pfizer INC. | $25,260.02 | 2019-2025 | |
| Janssen Biotech, INC. | $6,348.07 | 2019-2025 | Tremfya |
| Leo Pharma INC. | $2,681.54 | 2020-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $2,571.29 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Novartis Pharmaceuticals Corporation | $2,459.76 | 2019-2025 | |
| Lilly USA, LLC | $1,821.51 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,786.39 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $1,349.36 | 2019-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $919.26 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Genzyme Corporation | $827.71 | 2019-2025 | |
| Amgen INC. | $642.08 | 2019-2025 | Otezla, Otezla |
| Organogenesis INC. | $642.01 | 2020-2025 | Puraply Wound Matrix, Puraply, Novachor |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $551.15 | 2019-2025 | Cabtreo |
| Incyte Corporation | $447.07 | 2021-2025 | Opzelura |
Show all 47 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.